U.K. researchers reduced drug-seeking behaviors in rats by blocking their brain's NMDA-type glutamate receptor, which is vital on account of learning and memory, during the countermand of drug-associated memories. Researchers have known that recalling memories linked to previous drug use, such as environmental cues, can cause recovering remedy addicts to relapse.

The findings are published in the Aug. 13 impression of The Journal of Neuroscience.

In the study, researchers at the University of Cambridge trained rats to consort a light going on with receiving a dose of cocaine. They "reactivated" the memory by exposing the rats to the light without the cocaine infusion. Later, the rats continued to act behaviors that turned on the light or learned to perform new behaviors to try to get more cocaine.

The rats' cocaine-seeking behaviors were reduced after the researchers gave the animals a chemical that interfered with the NMDA-type glutamate receptor. When the particular treatment was given just prior to the reactivation session, it reduced or on the same level stopped drug-seeking behavior for up to a month; however, when given after or without the reactivation session, it had no effect on subsequent drug-seeking behaviors.

The findings suggest combining existing therapy with strictly timed use of NMDA receptor inhibitors may help addicts kick their habits. The U.S. Food and Drug Administration already has approved several NMDA receptor inhibitors, including the cough suppressant dextramethorphan and the Alzheimer's disease remedy memantine.

More information

The Center for Substance Abuse Treatment has more nearly conduct with addiction.

Two studies of more than 400 students at Ohio State University found those who did not cheat scored highest in tests of courage and empathy.

They also, perhaps unsurprisingly, scored higher than cheaters adhering tests of plain dealing.

Presenting the findings at the American Psychological Association conference, the researchers said the "academic heroes" were in the minority.

In the studies, students were asked if they had cheated in classes in the past 30 days and in the past year and whether they would be likely to cheat in the future.

The students also completed measures that examined their bravery, honesty and empathy.

Students who don't cheat seem to be in the nonage, and have plenty of opportunities to see their peers cheat and obtain the rewards with little risk of punishment
Professor Sara Staats

Those who scored in the top half - the so-called "academic heroes" - were less convenient to be in actual possession of reported cheating in the past 30 days and were not so much likely to intend to cheat in the future.

They in like manner reported they would feel more guilt if they cheated and did not rationalise cheating the way others did.

In addition they struggled to believe that their fellow students regularly committed academic dishonesty.

Personality

The honest students "have a more positive view of others", said study leader Professor Sara Staats.

She added: "Students who don't cheat seem to be in the minority, and have plenty of opportunities to see their peers cheat and receive the rewards with petty risk of punishment.

"We see avoiding cheating as a form of everyday gallantry in an academic setting."

The researchers added that other studies had shown that more than half - and sometimes up to 80% - of university students report that they have cheated.

Dr Paul Seagar, spokesperson for the British Psychological Society and lecturer at the University of Central Lancashire, said the findings were to be expected.

"These people probably have stronger personalities and are less likely to give into temptation."

free viagra
cialis
]]> Students who are bravest are least convenient to cheat, say US researchers.

Two studies of more than 400 students at Ohio State University found those who did not cheat scored highest in tests of courage and empathy.

They also, perhaps unsurprisingly, scored higher than cheaters adhering tests of plain dealing.

Presenting the findings at the American Psychological Association conference, the researchers said the “academic heroes” were in the minority.

In the studies, students were asked if they had cheated in classes in the past 30 days and in the past year and whether they would be likely to cheat in the future.

(Read the full post about ‘‘Bravest’ students do not cheat’…)

Researchers put 60 people end a driving simulation to proof steering, condensation and reactions.

North Dakota University found those on high dose anti-depressant courses had poorer driving skills.

But it was not clear whether it was the pills or the actual condition that caused the impairment and researchers related a larger study was now needed.

The participants were burst between those who were not on medication, those taking a low dose course and others upon the body a high dose.

We need a plenteous larger study, but there certainly seems to be more sort of link
Dr Holly Dannewitz, lead researcher

The simulation they were put through recreated a series of common driving situations, such as reacting to thicket lights, stop signs and traffic signals.

The team, which is presenting its findings at the Annual Convention of the American Psychological Association, found a significant difference between those not on medication and those on occult doses.

Overall, those not in succession medication got 69 points, those on disgraceful medication 65 and those forward high 54.

The team said it could be either the pills themselves or the condition which caused the problems.

Lead researcher Dr Holly Dannewitz said: "There is obviously more work to do on this. We need a much larger study, but there certainly seems to be some sort of link.

"I think people who are depressed, especially those on anti-depressants, should be aware of this suppose that they are driving or doing anything that relies on concentration and reaction skills."

Drivers in England and Wales are requested to inform the Driver and Vehicle Licensing Agency if they acquire a medical condition which could impair their driving and this does include depression.

However, driving restrictions are much more likely to be imposed on those who have a history of conditions such as epilepsy or strokes.

A spokesman for the DVLA said: "Assessments are achieved without ceasing a case-by-case basis. We would urge anyone who feels their driving is impaired by a medical class to contact us."

But Alison Kerry, from the mental health charity Mind, said: "Depression can affect people in many different ways, but one of the common symptoms is experiencing difficulty concentrating.

"However, it's important to state that everyone has highs and lows in condensation and reaction times, and a period of depression doesn't mean that you're a peril on the roads."
free viagra
cialis
]]> People put on anti-depressants may have impaired driving skills, a small US study suggests.

Researchers put 60 people end a driving simulation to proof steering, condensation and reactions.

North Dakota University found those on high dose anti-depressant courses had poorer driving skills.

But it was not clear whether it was the pills or the actual condition that caused the impairment and researchers related a larger study was now needed.

The participants were burst between those who were not on medication, those taking a low dose course and others upon the body a high dose.

(Read the full post about ‘Depression link to poor driving’…)

Pratchett acknowledges that through his success as an author - his Discworld succession has sold 55 million books worldwide - he is easily ingenious to afford to Aricept.

But he is concerned for other people with Alzheimer's who lack his means.

"I feel particularly provoked on behalf of early-onset patients because it feels like any treat with insolence and the younger you are the more abusive it is," he says.

"A lot of commonalty with early onset have got dependants the two junior and older and they're trying to hold down a job.

"It is a really nasty complaint and I cannot imagine cancer patients centre of life denied a drug like this in similar circumstances," Pratchett added.

Fear factor

He says that he has noticed a huge change in his condition after he started taking Aricept.

"If I'm not on the drug I'd find certain things difficult, doing up buttons so you get a line of buttons in the shirt done up right can be a problem," he reported.

Alzheimer's entirely affects older people

"In exposition I should be that much worse, but my wife has said that I'm better now than I was in the autumn."

But Pratchett says that the advantages of seizing the drug are wider than that.

"Alzheimer's scares people and at four o'clock in the morning it scares me, and Aricept is well worth having for the succor that it brings."

He said that the decision not to accord. it to early stage-wagon sufferers, if it were not that to cater free treatment for obesity and sexual impotence, indicated the NHS "priorities are not erect".

And the author also told Panorama that he thought it was possible that NICE's decision was in part shaped by the fact that Alzheimer's was a distemper predominantly affecting older people, who he said were thought of as "a softer target".

Panorama: The Postcode Lottery: It Could Be You will be on BBC One at 8.30pm on Monday 18 August.
free viagra
cialis
]]> NICE said that Aricept, which costs about 2.50 a day, did not acquire enough of a difference to recommend it for all patients and therefore was not righteousness value for money.

Pratchett acknowledges that through his success as an author - his Discworld succession has sold 55 million books worldwide - he is easily ingenious to afford to Aricept.

But he is concerned for other people with Alzheimer’s who lack his means.

“I feel particularly provoked on behalf of early-onset patients because it feels like any treat with insolence and the younger you are the more abusive it is,” he says.

“A lot of commonalty with early onset have got dependants the two junior and older and they’re trying to hold down a job.

(Read the full post about ‘Pratchett criticises drugs ruling’…)

Dorothy Wray, from Kimberley Hill in the Waterside, died in February - six months after being admitted to hospital following a fall.

Her granddaughter, Joanne, said the hospital did not tell other patients that which her grandmother had contracted.

"There didn't seem to be some attempts to isolate the ward," she said.

"We feel very strongly that my grandmother was on a ward with other patients who were not aware."

A hospital spokesman said patients were moved to single isolation rooms as soon as was possible.

"We are challenged through a 40-year-old hospital," he said.

"There are not enough isolation rooms, but that is being remedied."
free viagra
cialis
]]> The family of a Londonderry woman who died hind contracting the C. difficile bug at Altnagelvin hospital has hit lacking at the way she was treated.

Dorothy Wray, from Kimberley Hill in the Waterside, died in February - six months after being admitted to hospital following a fall.

Her granddaughter, Joanne, said the hospital did not tell other patients that which her grandmother had contracted.

“There didn’t seem to be some attempts to isolate the ward,” she said.

“We feel very strongly that my grandmother was on a ward with other patients who were not aware.”

A hospital spokesman said patients were moved to single isolation rooms as soon as was possible.

(Read the full post about ‘Family anger at C. diff ’secret’’…)

"An internal inquiry has been ordered," Shakti Kumar Gupta, head of administration for the state-run All-India Institute of Medical Sciences (AIIMS), told AFP.

"We have constituted a committee to inquire into this."

The country's biggest hospital, where thousands go for free rise above therapeutic treatment, has been in the spotlight after a non-profit freedom from disease group publicised infant deaths that occurred during clinical trials over the last 30 months, some of them associated with foreign drug companies.

Some 4,142 babies admitted in the hospital were in clinical trials since January 1, 2006, more than half of them under the age of some, the hospital told the group in response to a request under freedom-of-information laws.

The non-profit's founder uttered it hoped to publicise the need for better regulation of India's booming outsourced clinical trial business, estimated at around 120 million dollars last year and growing at 25 percent annually.

"When you are not able to afford a particular treatment in a privy freedom from disease be troubled centre you look encourage to getting free medication in something like this," said Rahul Verma, of the Uday Foundation in favor of Congenital Defects and Rare Blood Groups, which filed the request.

"We wanted to know what are the socioeconomic grade of these people? Are they given consent forms and counselling?"

Verma said the hospital did not collect for use information upon the incomes of the families in the infant trials.

India has become a in favor destination for clinical research because of its elephantine population, varied population and low costs. Trials here require to be paid 40 to 60 percent of what they would in developed countries.

Consulting firm Ernst & Young has said the outsourced clinical research emporium in India could be augmented to pair billion dollars by 2010.

But through many of those who participate in trials poor and often literate, by few other options for care, questions persist besides the ethics of doing the human testing of new drugs here.

Hospital official Gupta said the AIIMS trials were cleared by an internal moral committee and followed guidelines laid down by the government.

He also said the infants who died were in control groups and not among those receiving experimental medical intervention.

"All these children were very seriously ill," said Gupta.

"No child has died which was in the intervention group."

The health minister has backed the facility so far but also said more appropriate control was in the works.

"Earlier we had guidelines on how trials need to subsist conducted," said Health Minister Anbumani Ramadoss, according to a narrate in the Times of India Wednesday. "Soon we will have a law."

A five-member inquiry committee has been asked to succumb its findings within a week.

Representatives of the Academy of Molecular Imaging and other groups said that data collected from a nationwide indefatigable registry showed positron emission tomography (PET) scans helped doctors adjust their treatment plans during the term of roughly one-third of enrolled patients.

"This is a broadly applicable technique to cancers in general," Dr. David Mankoff, a University of Washington radiologist, said on behalf of several industry associations.

The groups, which also include several medical societies, initially had asked Medicare to lift restrictions upon payments on this account that nine cancers: brain, cervical, bladder, small-cell lung, ovarian, testicular, prostate, kidney and pancreatic cancers.

Medicare, which covers 44 million somewhat advanced in life and disabled Americans, said in 2005 it would cover the nine cancers allowing that patients were enrolled in the recording. In March, the groups before-mentioned they had enough complaint to support easing the policy by allowing routine coverage without registration.

The government agency is seeking advice from outside medical advisers before deciding whether to enlarge payments or otherwise change the current program.

Some panelists questioned the data's ability to support thus many cancer uses, especially after several researchers commissioned by Medicare said the condition of available studies was poor to moderate.

"I don't see for what reason you make the leap," said panel member and consumer representative Linda Bergthold "The humor of the data ... was really stunningly poor."

Eliminating the patient enrolment requirement would allow greater use of PET among Medicare patients, in duty for the cause that it would be easier for doctors to order the scans.

That could be a boost for PET scan makers such as General Electric Co, Siemens AG and Philips Electronics NV.

More than 2 a thousand thousand PET scans are given in the United States each year, according to Philips. The companies carry into practice not tear asunder out PET scan sales figures, and a spokeswoman for Medicare declared data on how much the agency has spent for the test was not readily available.

There has been disagreement over the effectiveness of PET scans compared to other imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) scans in detecting cancer cells.

With PET, patients are injected with radioactive sugars that collect in metabolically active parts of the corpse, which could signal growth and possibly cancer.

The ability to pinpoint biologically active areas is a key difference between PET and CT scans or MRI scans. While PET can find some cancers that CT and MRI miss, its images can exist less detailed or trigger fallacious positives.

Medicare is expected to make a draft decision in January and a final ruling in April.

(Editing by Tim Dobbyn)

The American Academy of Family Physicians offers these guidelines when choosing safe toys:

• Make sure each toy is sturdy, well-made, and appropriate concerning your babe's age.
• Don't let your baby play with toys that have sharp edges or points, or small parts.
• Make sure parts sudden securely and are not loose.
• Read labels to check for safety information. Look for toys that are non-toxic, washable and hygienic.
• Don't impediment your baby perform with in any degree toys that are smaller than 1 3/4 inches in central chord or 2 inches long, as these may pose a choking hazard.

More than 50 percent of men age 50 and older have lower urinary tract symptoms, including increased urination commonness and spur, straining, intermittence, incomplete emptying or a weak urinary stream. Current drugs used to treat the rank can produce side effects similar as dizziness, low blood pressure and sexual dysfunction.

In this study that included 1,056 men in 10 countries, the men were randomly divided into five groups that received either a placebo or tadalafil doses of 2.5, 5.0, 10.0 or 20.0 milligrams a day. All doses of the drug were paramount to a placebo for relieving lower urinary tract symptoms (LUTS), with statistically significant effects at four, eight and 12 weeks.

The study, which included researchers from drug maker Lilly, is published in the October issue of The Journal of Urology.

"Since reports of erectile dysfunction (ED) incidence, pathophysiology and treatment acquire shown a possible link betwixt [enlarged prostate] and ED. PDE5 inhibitors like tadalafil (Cialis) have received increased alertness for treating BPH LUTS, although they are currently only approved for ED. The half-life of tadalafil is 17.5 hours, structure it suitable as once daily therapy. Although the precise mechanism of action by which PDE5 inhibitors may alleviate LUTS is not completely understood, several putative mechanisms are currently while burdened with exploration." researcher Dr. Claus G. Roehrborn, professor of urology at the University of Texas Southwestern Medical Center at Dallas, said in a journal news release.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about enlarged prostate.

The discovery will lend aid doctors to swiftly identify patients who need chemotherapy, boosting their chances of survival, the study said.

"We only want to application chemotherapy where we conceive there's a good chance it will help. This test determine help use determine that," said co-author Robert Wilson, a surgeon at The James Cook University Hospital in Middlesbrough, England.

Colorectal, or bowel, cancer is the third most deadly form of cancer worldwide, accounting by reason of nearly 680,000 deaths in 2007, according to the World Health Organisation.

Almost three-quarters of all cases -- linked to diet and lifestyle -- occur in people with one foot in the grave 65 and over.

"There is a desperate need during more efficient treatments in quest of bowel cancer," noted Mark Matfield of the Association for International Cancer Research, commenting on the study.

"The problem is identifying what one. cancers need which treatment. This discovery may show us the way to carry into effect that and help keep a lot of lives," he said.

Stem-cell researchers led by Christopher Hutchison of Durham University examined tissue samples from 700 bowel cancer patients.

They found that patients who had a stem cell marker protein called "Lamin A" were more likely to have an especially aggressive and viscous form of the disease.

If detected in the early stages of the cancer's progression, the marker could signal the need for chemotherapy in addition to the more standard use of surgery to remove tumours, they concluded.

Scientists identify four stages in the development of bowel cancer. In the first two stages -- before patients develop lymph nodes -- patients normally have an operation to remove cancerous tissue.

They are rarely given chemotherapy, which can sometimes cause additional harm then good.

But the new study shows that one third of these patients force of will express the Lamin A stem small room marker, and would thus subsist good candidates for the more invading form of treatment.

The study was published in the open-access science journal Public Library of Science One (PLoS One).